Elevated plasma levels of CXCL16 in severe COVID-19 patients
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.09.07.21263222: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements; 2. Sex as a biological variable not detected. Randomization Participants: ODYSSEY is a double-blinded Phase 3 study with a planned randomization of a total of 300 hospitalized severely ill COVID-19 patients (Clinicaltrials.gov: NCT04326426). Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources CXCL16 levels in plasma were determined with an enzyme□linked immunosorbent assay (ELISA) assay (Thermofisher ID: # EHCXCL16) performed on plasma collected at baseline in cases and … SciScore for 10.1101/2021.09.07.21263222: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements; 2. Sex as a biological variable not detected. Randomization Participants: ODYSSEY is a double-blinded Phase 3 study with a planned randomization of a total of 300 hospitalized severely ill COVID-19 patients (Clinicaltrials.gov: NCT04326426). Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources CXCL16 levels in plasma were determined with an enzyme□linked immunosorbent assay (ELISA) assay (Thermofisher ID: # EHCXCL16) performed on plasma collected at baseline in cases and in a set of healthy controls (assay range 2.74-2000 pg/mL). Thermofisher IDsuggested: NoneDNA sample size distributions are profiled by a Fragment Analyzer (Advanced Analytics) or BioAnalyzer (Agilent Technologies), to assess sample quality and integrity. BioAnalyzersuggested: (BioAnalyzer 2100, RRID:SCR_019715)Whole genome sequencing (WGS) libraries were prepared using the Truseq DNA PCR-free Library Preparation Kit. WGSsuggested: NonePaired-end 150 bp reads were aligned to the GRCh37 human reference (BWA-MEM v0.7.8) and processed with GATK best-practices workflow (GATK v3.4.0). BWA-MEMsuggested: (Sniffles, RRID:SCR_017619)GATKsuggested: (GATK, RRID:SCR_001876)All high quality variants obtained from GATK were annotated for functional effects (intronic, intergenic, splicing, nonsynonymous, stopgain and frameshifts) based on RefSeq transcripts using Annovar31. RefSeqsuggested: (RefSeq, RRID:SCR_003496)Additionally, Annovar was used to match general population frequencies from public databases (Exac, gnomAD, ESP6500, 1000g) and to prioritize rare, loss-of-function variants. Annovarsuggested: (ANNOVAR, RRID:SCR_012821)Linear models adjusted for PC, age and sex were conducted in PLINK. PLINKsuggested: (PLINK, RRID:SCR_001757)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04326426 Enrolling by invitation ODYSSEY: A Study to Investigate the Efficacy of Tradipitant … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
